GeoVax Labs, Inc. (Nasdaq: GOVX) today reported financial results for the second quarter of 2026 and provided a business update, highlighting continued execution toward the planned initiation of its pivotal GEO-MVA immunobridging study under an expedited regulatory pathway. The company is also advancing its Gedeptin immuno-oncology program.
During the quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study, established through formal Scientific Advice discussions with the European Medicines Agency (EMA). Activities included clinical study readiness, manufacturing preparedness, and engagement with government and public health stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and CEO. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA)-based vaccine candidate for protection against mpox and smallpox. The program is advancing under an expedited regulatory pathway supported by EMA Scientific Advice, designed to support potential approval through a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine. Clinical-grade vaccine has been successfully manufactured and released under cGMP for the planned study.
GeoVax continues to advance Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin's localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies by improving responsiveness in immunologically resistant tumors. GeoVax maintains an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4,426,578 ($0.97 per share) for the quarter ended June 30, 2026, compared to $5,369,783 ($8.74 per share) in the same period of 2025. The decrease in net loss was primarily due to lower research and development expenses, which fell to $3,110,508 from $4,728,998, reflecting reduced spending on discontinued GEO-CM04S1 activities after the BARDA contract termination. General and administrative expenses also decreased to $1,331,564 from $1,542,190. Cash and cash equivalents stood at $3.1 million as of June 30, 2026.
GeoVax is prioritizing resources toward programs with strong clinical differentiation, regulatory clarity, and commercial opportunity, including execution of the GEO-MVA pivotal immunobridging study, advancement of scalable manufacturing capabilities, and Gedeptin combination immunotherapy strategies. The company believes GEO-MVA is uniquely positioned to help address the growing need for diversified global MVA vaccine manufacturing capacity supporting public health preparedness and biodefense resilience.
Additional information is included in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. For more information, visit www.geovax.com.
